Stay updated on First-Line Tarlatamab Combo in ES-SCLC Clinical Trial
Sign up to get notified when there's something new on the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page.

Latest updates to the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page’s footer revision/version was updated from v3.5.2 to v3.5.3, indicating a site build change without altering the displayed clinical trial study information.SummaryDifference0.0%

- Check23 days agoChange DetectedRevision label updated to v3.5.2; revision v3.5.0 was removed.SummaryDifference0.0%

- Check52 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0 is displayed on the page. This change reflects a minor version update with no apparent impact on content or user actions.SummaryDifference0.0%

- Check59 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check66 days agoChange DetectedNew date stamps and results-posting status were added (e.g., 'No Results Posted' on 2026-03-03), and older entries were removed. The overall study details, eligibility criteria, and planned interventions remain unchanged.SummaryDifference0.2%

- Check88 days agoChange Detected- Revision: v3.4.2 has been added. The government funding notice and Revision: v3.4.1 banner have been removed; no study content or eligibility information was changed.SummaryDifference0.3%

Stay in the know with updates to First-Line Tarlatamab Combo in ES-SCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the First-Line Tarlatamab Combo in ES-SCLC Clinical Trial page.